Business
enGene Reports Full Year 2025 Financial Results and Provides Business Update
BOSTON & MONTREAL, December 22, 2025--enGene Holdings Inc. (Nasdaq: ENGN, "enGene" or the "Company"), a clinical-stage, non-viral genetic medicines company, today announced its financial results for the full year ended October 31, 2025, and provided a business update.
About this update from Engene Holdings Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/c0cfad3877ea05b60ec46e8bffbe3c08"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/pIjh7ucmVRBowB6okKWQLg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/c0cfad3877ea05b60ec46e8bffbe3c08","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/fHQhnf4190Xuw32IjOhaaA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/c0cfad3877ea05b60ec46e8bffbe3c08","width":1024,"height":512}},"lazy":false},{"type":"text","content":"Completed enrollment in LEGEND’s pivotal cohort with 125 patients in high-risk, BCG-unresponsive NMIBC with carcinoma in situ","length":125,"tagName":"p","attribs":{}},{"type":"text","content":"Reported preliminary 6-month complete response rate (62%) in pivotal cohort patients enrolled under amended LEGEND protocol","length":123,"tagName":"p","attribs":{}},{"type":"text","content":"enGene selected for FDA’s CDRP Program to support CMC readiness","length":63,"tagName":"p","attribs":{}},{"type":"text","content":"Biologic License Application (BLA) submission for detalimogene planned for 2H 2026","length":82,"tagName":"p","attribs":{}},{"type":"text","content":"Cash and marketable securities plus proceeds from November financing expected to provide cash runway into 2H 2028","length":113,"tagName":"p","attribs":{}},{"type":"text","content":"BOSTON & MONTREAL, December 22, 2025--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, "enGene" or the "Company"), a clinical-stage, non-viral genetic medicines company, today announced its financial results for the full year ended October 31, 2025, and provided a business update.","length":309,"tagName":"p"},{"type":"text","content":""We are closing 2025 in a position of strength: enrollment in LEGEND's pivotal cohort is complete and the recent data update from the LEGEND pivotal cohort supports an emerging, competitive profile for the use of detalimogene as the first choice therapy in BCG-unresponsive NMIBC if approved," said Ron Cooper, President and Chief Executive Officer. "With recent acceptance into FDA’s CDRP pro...